Biotech Startups

Brink Therapeutics is a TechBio company developing programmable integrases, a nuclease-free platform for precise, large-payload genomic insertion of therapeutic genes for cell and gene therapy. It combines directed evolution, metagenomics, and generative AI to engineer insertion enzymes for applications such as CAR-T manufacturing and correcting monogenic diseases, and works with pharma and biotech partners on licensing and co-development.

1 investor

Broadwing Bio develops antibody-based therapies targeting genetically validated ophthalmology conditions, particularly geographic atrophy and glaucoma, to preserve vision and prevent blindness. The company builds on naturally occurring genetic variants to create novel treatments for ocular diseases.

1 investor

Bruker Cellular Analysis develops technologies for live single-cell biology research, combining optofluidics, live single-cell imaging, functional cell biology, and multiomic data to study cellular function and molecular mechanisms. It serves scientists in academia, biotech and pharmaceutical companies, and contract research organizations, supporting work in cell therapy, therapeutic antibody discovery, vaccine development, and cell line development.

1 investor

BryoSphere Biotechnologies uses a proprietary moss biomanufacturing platform to produce bioactive ingredients for skincare, targeting concerns such as hyperpigmentation, inflammation, and aging. It supplies these sustainably sourced ingredients to beauty brands.

1 investor

BSafe Biotech develops a biological crop protection product for agriculture, described as a new mode of action for biological pest and disease control.

1 investor

BTB Therapeutics develops a non-opioid analgesic aimed at addressing the opioid crisis, along with a pipeline of RNA-modifying compounds for rare genetic diseases and to enhance cancer immunotherapy. The company is based on transcriptomics drug discovery programs from Kyoto University, with a US parent and an operating subsidiary in Kyoto, Japan.

1 investor

BÜHLMANN Laboratories is a life science company based in Switzerland.

1 investor

BUILT DNA manufactures synthetic DNA using its Regenerative DNA Assembly platform and a reusable fragment inventory, offering turnkey products such as clonal plasmid DNA, whole-plasmid synthesis, linear DNA templates, and pooled plasmid libraries. It serves researchers and innovators needing reliable DNA supply for applications including mRNA and saRNA production and high-throughput discovery.

1 investor

Burlington Bio applies mechanical and materials engineering methods to biological systems, developing tunable biopolymer networks that turn unused nutrient-rich food byproducts into upcycled, clean-label ingredients. The company targets food producers with solutions aimed at preserving taste, texture, and functionality while improving nutrition.

1 investor

Burna builds AI agents that read clinicians' free-text clinical notes to identify and grade adverse events against the specified CTCAE version, score drug attribution, and draft IRB, sponsor, and FDA safety reports for investigator review and sign-off. It targets research sites, pharma and biotech companies, and CROs running clinical trials.

1 investor

Byorna develops a bioproduction platform that uses eukaryotic cell biofactories to manufacture high-quality messenger RNA (mRNA) at lower cost, isolating the mRNA in cellular subcompartments for extraction and GMP-grade production. Its technology targets mRNA-based therapeutics including vaccines for infectious diseases, cancer treatments, and RNA gene therapy for rare diseases.</parameter> <parameter name="founders">[]

1 investor

C2N Diagnostics develops and commercializes blood-based diagnostic tests for Alzheimer's disease and other neurodegenerative conditions, using proprietary LC-MS/MS mass spectrometry to detect brain amyloid pathology. Its PrecivityAD, PrecivityAD2, and Precivity-ApoE tests serve health care professionals evaluating patients with cognitive impairment, available across all 50 US states and the District of Columbia.

1 investor

CABB Group is a contract development and manufacturing company (CDMO) specializing in the production of customized, complex molecules for crop sciences, life sciences, and performance materials industries. The company offers custom fine chemical manufacturing services as well as fine chemicals including reagents, building blocks, and advanced intermediates for downstream applications.

1 investor

CaCO₃ Biotech recovers whole mollusk shells that are byproducts of Quebec's seafood industry and cultures nacre (mother-of-pearl) from them, turning marine coproducts otherwise destined for landfill into usable materials. It supplies natural ingredients for cosmetics, biomaterials, jewelry, and decorative or craft applications, positioning itself as the first company to commercialize such products in North America, with operations in the Gaspésie region.

1 investor

Cadex Genomics develops blood-based diagnostic assays for cancer patients. Its product Alibrex is a real-time therapy monitoring blood test that measures changes in circulating tumor DNA to assess whether a stage IV cancer patient's treatment is effective within about 12 days of the first dose, regardless of tumor or therapy type.

1 investor

Cadila Pharmaceuticals is one of India's largest privately held pharmaceutical companies engaged in the discovery, development, and manufacturing of affordable generic and innovative medicines for patients globally. The company operates across 100 countries in seven regions, with a focus on making quality healthcare accessible and cost-effective.

1 investor

Cadmus Animal Health develops an immunotherapeutic to treat chronic periodontal disease caused by the bacterium Porphyromonas in companion animals. It operates in the veterinary/animal health biotech sector.

1 investor

CAGE Bio is a clinical-stage biotech developing localized topical treatments for dermatology, inflammation, and immunology conditions using its proprietary deep eutectic ionic liquid platform. The technology enables small and large molecules such as proteins and nucleic acids to penetrate the skin, aiming to match the efficacy of systemic drugs while avoiding their side effects.

1 investor

Calaris develops saliva-based, point-of-care diagnostic tests for early detection of liver disease and head & neck cancer, using validated salivary biomarkers, multiplexing, and AI/ML algorithms to generate risk scores. The tests are designed for use in primary care and community health settings to enable non-invasive screening.

1 investor

Calder Biosciences develops protein-based subunit vaccines using its 3D-Vaxlock technology, which uses dityrosine crosslinking to lock immunogens into the shape they hold on a virus surface for improved antibody responses. Its engineered immunogens aim to offer better safety, efficacy, thermostability, and reduced cold chain requirements against infectious diseases.

1 investor

CALDRE is a Switzerland-based biotech spin-out developing liver-directed GalNAc-siRNA therapeutics, including its claudin-3 targeting candidate ClagalsiR, to restore bile flow and prevent fibrosis. It aims to treat cholestatic and fibrotic liver diseases such as primary sclerosing cholangitis and primary biliary cholangitis and reduce the need for liver transplantation.

1 investor

Calico is a research and development company studying the biology of aging and translating those insights into potential medicines for age-related diseases. It combines basic research, computational biology and machine learning, and drug development to advance early- and clinical-stage compounds.

1 investor

Calistoga Pharmaceuticals is a pharmaceutical company. The available page content does not describe its therapeutic focus or products.

1 investor

Caliz develops and supplies biotechnological active ingredients (bioactives) and offers custom development of biological assets for R&D teams and formulators. The company provides a catalog of bioactive ingredients along with information on their mechanisms of action for new product development.

1 investor